Read by QxMD icon Read


Sanna Iivanainen, Jussi P Koivunen
BACKGROUND: Most clinical trials have investigated PD-(L)1 agents until disease progression or severe side effects, but the optimal duration of the treatment remains to be elucidated. Our institutional guideline has restricted maximal PD-(L)1 therapy length to 6 months, and therefore our cohort provides a unique opportunity to investigate the effects of short PD-1 therapy. METHODS: We retrospectively collected all patients who had been treated with PD-1 therapy for metastatic cancer at Oulu University Hospital from 2014 to 2018...
October 31, 2018: Oncology
Luke T Juckett, Doug I Lin, Russell Madison, Jeffrey S Ross, Alexa B Schrock, Siraj Ali
BACKGROUND: The Polycomb Repressive Complex 1 (PRC1) regulates epigenetic silencing and is manifestly linked to rare cancer types. The X-linked BCOR gene (BCL-6 Corepressor) is a member of the PRC1 complex and potentiates transcriptional repression through BCL6 binding of PRC1. Accumulating evidence suggests that internal tandem duplications (ITD) of BCOR are oncogenic drivers in a subset of pediatric sarcomas and rare adult tumors. OBJECTIVE: We reviewed the genomic profiles of a large series of advanced cancer patients to determine the frequency and genomic spectrum of ITD of BCOR across cancer...
October 31, 2018: Oncology
Dai Inoue, Shuhei Sekiguchi, Wataru Yamagata, Gen Maeda, Daiki Yamada, Shun Fujiwara, Shiori Itou, Masamichi Kurihara, Yuko Hijioka, Kohei Shimoji, Junko Fujiki, Ayano Nakazono, Hideyuki Horike, Atsushi Yoshioka, Yuki Ogura, Fumihiko Hatao, Kazuhiro Imamura, Shin Namiki
OBJECTIVES: The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. METHODS: The association of overall survival (OS) in second-line chemotherapy and the clinicopathological findings including NLR were analyzed retrospectively. The selection criteria were patients who received second-line chemotherapy between January 2010 and June 2015, had histologically confirmed gastric adenocarcinoma, and were followed up until death or for 180 days or longer...
October 26, 2018: Oncology
Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Hiroshi Matsubara, Yoji Sasaki, Koichi Achiwa, Akira Kanamori, Hajime Sumi, Takanori Hirai, Koji Nonogaki, Tomoyuki Tsuzuki, Masanori Kuroiwa, Masashi Hattori, Shinya Maruta, Takeshi Hiramatsu, Masahiko Ando, Senju Hashimoto, Yoshiki Hirooka
OBJECTIVE: To evaluate the efficacy and safety of alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. METHODS: Patients with histologically proven, unresectable pancreatic cancer treated with chemotherapy not including S-1 as first-line therapy were randomly assigned to receive either daily or alternate-day treatment with S-1. The primary end point was overall survival (OS), and the secondary end points were progression-free survival (PFS), time to treatment failure (TTF), response rate, and adverse events...
October 26, 2018: Oncology
Paula Carrio-Cordo, Michael Baudis
Cancers arise from the accumulation of somatic genome mutations, with varying contributions of intrinsic (i.e., genetic predisposition) and extrinsic (i.e., environmental) factors. For the understanding of malignant clones, precise information about their genomic composition has to be correlated with morphological, clinical, and individual features in the context of the available medical knowledge. Rapid improvements in molecular profiling techniques, the accumulation of a large amount of data in genomic alterations in human malignancies, and the expansion of bioinformatic tools and methodologies have facilitated the understanding of the molecular changes during oncogenesis, and their correlation with clinicopathological phenotypes...
October 26, 2018: Oncology
Sook-Hee Hong, Ho Jung An, Kihyun Kim, Seung Sei Lee, Yun-Gyoo Lee, Young-Jin Yuh, I Cheon Park, Yee Soo Chae, Tae-Won Jang, Jin-Hyoung Kang
OBJECTIVES: Anti-angiogenic agents are reported to exert clinical activity on epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancers. We evaluated the clinical outcomes of nintedanib and docetaxel in refractory NSCLC according to EGFR mutation status during the Korean nintedanib named patient program. METHODS: Docetaxel was administered either 75 or 37.5 mg/m2 on D1, D8 q every 3 weeks for 4-6 cycles plus nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity...
October 26, 2018: Oncology
Kaori Hayashi, Seiichiro Mitani, Hiroya Taniguchi, Hirofumi Yasui, Kei Muro, Keita Mori, Takuji Gotoda, Kentaro Yamazaki
OBJECTIVE: Anti-epithelial growth factor receptor (EGFR) antibodies cetuximab (Cmab) and panitumumab (Pmab) have shown survival benefit for metastatic colorectal cancer (mCRC) patients. This study aimed to compare Pmab and Cmab according to the interval between bevacizumab discontinuation and anti-EGFR antibody initiation (bevacizumab-free interval; BFI). METHODS: We retrospectively evaluated mCRC patients who received Cmab or Pmab in combination with irinotecan at two institutions...
October 25, 2018: Oncology
Aslı Suner, Brian I Carr, Hikmet Akkiz, Gökhan Karakülah, Oguz Üsküdar, Kendal Yalçın, Sedef Kuran, Yaman Tokat, Sezai Yilmaz, Ayşegül Özakyol, Salih Tokmak, Tuğsan Ballı, Mehmet Yücesoy, Halil İbrahim Bahçeci, Abdulalh Ülkü, Tolga Akçam, Kamil Yalçın Polat, Nazım Ekinci, Halis Şimşek, Necati Örmeci, Abdulalh Sonsuz, Mehmet Demir, Murat Kılıç, Ahmet Uygun, Ali Demir, Anıl Delik, Burcu Arslan, Figen Doran, Engin Altıntaş, Tuncer Temel, Ahmet Bektaş
The hepatocellular carcinoma (HCC) tumor marker alpha-fetoprotein (AFP) is only elevated in about half of the HCC patients, limiting its usefulness in following the effects of therapy or screening. New markers are needed. It has been previously noted that the inflammation markers C-reactive protein (CRP) and platelet-lymphocyte ratio (PLR) are prognostically important and may reflect HCC aggressiveness. We therefore examined these 2 markers in a low-AFP HCC cohort and found that for HCCs > 2 cm, both markers significantly rise with an increasing maximum tumor diameter (MTD)...
October 18, 2018: Oncology
Jee Hung Kim, Hyung Soon Park, Su Jin Heo, Sang Kyum Kim, Jung Woo Han, Kyoo-Ho Shin, Seung Hyun Kim, Hyuk Hur, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong-Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Hyo Song Kim
BACKGROUND: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). METHODS: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. RESULTS: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4...
October 18, 2018: Oncology
Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Masahito Nakano, Manabu Satani, Syuusuke Okamura, Yu Noda, Naoki Kamachi, Ryoko Kuromatsu, Miwa Sakai, Mika Nomiyama, Toru Kuwano, Masatoshi Tanaka, Hironori Koga, Takuji Torimura
BACKGROUND: Transcatheter arterial chemoembolization (TACE) is a standard therapy used in the treatment of intermediate hepatocellular carcinoma (HCC). Recently, balloon-occluded TACE (B-TACE) has been developed. PURPOSE: This study aimed to clarify the effects of B-TACE in patients with HCC, with a focus on which drug is suitable to suspend in Lipiodol for B-TACE. METHODS: We retrospectively evaluated 35 patients with HCC treated with B-TACE...
October 5, 2018: Oncology
Nelli Roininen, Sari Takala, Kirsi-Maria Haapasaari, Arja Jukkola-Vuorinen, Johanna Mattson, Päivi Heikkilä, Peeter Karihtala
OBJECTIVES: Due to the rarity of breast carcinomas with neuroendocrine features (NEBC), the knowledge on their biology is very limited but the identification of their biology and prognostic factors is essential to evaluate both pathogenesis and possible targeted treatment options. We assessed the expression of the well-characterized prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in NEBC. METHODS: We assessed the immunohistochemical expression of neuron-specific enolase (NSE), thymidylate synthase (TS), p27, CD56, menin, and somatostatin receptor type 2A (SSTR-2A) in a series of 36 NEBC and 45 invasive ductal carcinomas (IDC)...
October 3, 2018: Oncology
Morikazu Miyamoto, Masashi Takano, Hitoshi Tsuda, Hiroko Matuura, Tadashi Aoyama, Hiroaki Soyama, Kento Kato, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Ayako Suzuki, Junko Hirata, Kenichi Furuya
OBJECTIVE: The clinical significance of lymphocyte infiltration (LI) at the invasive front in endometrial carcinomas (EC) has not been determined. The aim of the current study was to evaluate the association between zone formation of LI at the invasive front of the tumor margin and prognoses of the patients with EC. METHODS: All available pathological slides of the enrolled cases were reviewed, and the degree of LI at the invasive front was categorized into 2 groups: strong LI and weak LI...
October 3, 2018: Oncology
Aurélie Thuleau, Caroline Gilbert, Pierre Bauër, Séverine Alran, Virginie Fourchotte, Eugénie Guillot, Anne Vincent-Salomon, Jean-Charles Kerihuel, José Dugay, Vincent Semetey, Irène Kriegel, Isabelle Fromantin
We developed a new transcutaneous method for breast cancer detection with dogs: 2 dogs were trained to sniff skin secretion samples on compresses that had been worn overnight by women on their breast, and to recognize a breast cancer sample among 4 samples. During the test, the dogs recognized 90.3% of skin secretion breast cancer samples. This proof-of-concept study opens new avenues for the development of a reliable cancer diagnostic tool integrating olfactory abilities of dogs.
October 2, 2018: Oncology
Laurence Bigay-Gamé, Suzanna Bota, Laurent Greillier, Isabelle Monnet, Anne Madroszyk, Romain Corre, Bénédicte Mastroianni, Lionel Falchero, Julien Mazières, Hélène Colineaux, Benoit Lepage, Christos Chouaid
OBJECTIVES: The aim of this study was to describe the demographic and clinico-pathological characteristics of lung cancer in patients younger than 40 years. MATERIALS AND METHODS: This was a prospective study performed within the Groupe Français de Pneumo-Cancérologie. Consecutive patients diagnosed with lung cancer before the age of 40 years were eligible. Data on demographics, medical history, clinico-pathological characteristics, treatment and overall survival were analysed...
October 2, 2018: Oncology
Tomoyuki Wakahara, Kiyonori Kanemitsu, Tetsuo Maeda, Takuro Yoshikawa, Shinobu Tsuchida, Nozomi Ueno, Akihiro Toyokawa
OBJECTIVES: This study aimed to investigate the validity of laparoscopic gastric cancer surgery in elderly patients. METHODS: A total of 202 patients who underwent laparoscopic gastrectomy for gastric cancer between January 2007 and December 2016 were divided into an elderly group (age ≥75 years, n = 36) and a control group (age < 75 years, n = 166). The patients' clinicopathological data were reviewed. RESULTS: The overall morbidity rate was relatively higher in the elderly group (16...
October 2, 2018: Oncology
Jason Ho, Matthew Ware, Justin Law, Aaditya Nagaraj, Shilpa Jain, Jesse Rios, Reynaldo Calderon, Barry Toombs, Andrew Anderson, Collin Bray, Steven Curley, Stuart James Corr
Large animal models are important tools for hepatocellular carcinoma (HCC) research, especially in studies of hepatic vasculature, interventional techniques, and radiofrequency or microwave hyperthermia. Currently, diethylnitrosamine (DENA)-induced HCC in pigs is the only large animal model for in situ HCC with a tumor latency of 10-26 months. While phenobarbital (PB) is often used to accelerate DENA-induced HCC in rodents, it has not been previously studied in the porcine model. Therefore, we hypothesize that the addition of PB in the DENA-induced HCC porcine model will accelerate tumor latency compared to DENA alone...
September 28, 2018: Oncology
Raz Mutai, Hadar Goldvaser, Tzipora Shochat, Idit Peretz, Aaron Sulkes, Rinat Yerushalmi
BACKGROUND: Lymphovascular invasion (LVI) is considered a negative prognostic factor in early breast cancer, but its role in decision-making regarding adjuvant chemotherapy is unclear in the current era of molecular profiling. This study sought to evaluate the association of LVI status with the recurrence score (RS) on the multigene Oncotype DX (ODX) assay and its impact on outcome. METHODS: Patients with early estrogen receptor-positive breast cancer who underwent ODX analysis in 2005-2012 were retrospectively identified...
September 25, 2018: Oncology
Paul Martin Putora, Maurie Markman
No abstract text is available yet for this article.
September 25, 2018: Oncology
Akira Yamamoto, Yuji Toiyama, Yoshinaga Okugawa, Susumu Saigusa, Shozo Ide, Hiroyuki Fujikawa, Junichiro Hiro, Hiromi Yasuda, Shigeyuki Yoshiyama, Masaki Ohi, Toshimitsu Araki, Masato Kusunoki
OBJECTIVE: This study aimed to investigate clinicopathological responses and oncological outcome in patients receiving short- or long-course chemoradiotherapy (CRT) and to assess the predictive factor for recurrence in each treatment. METHODS: A total of 118 rectal cancer patients receiving preoperative CRT were enrolled. Clinicopathological responses and oncological outcome in patients receiving short- or long-course CRT were investigated. RESULTS: Despite there being no significant differences in the prognosis of disease-free survival (DFS) based on TNM stage classification in patients receiving long-course CRT, patients with advanced stage demonstrated poor DFS after short-course CRT...
September 18, 2018: Oncology
Markus Glatzer, Cedric Michael Panje, Charlotta Sirén, Nikola Cihoric, Paul Martin Putora
Decision making is one of the most complex skills required of an oncologist and is affected by a broad range of parameters. For example, the wide variety of treatment options, with various outcomes, side-effects and costs present challenges in selecting the most appropriate treatment. Many treatment choices are affected by limited scientific evidence, availability of therapies or patient-specific factors. In the decision making process, standardized approaches can be useful, but a multitude of criteria are relevant to this process...
September 18, 2018: Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"